Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib + vemurafenib + cetuximab for first-line unresectable BRAF V600E colorectal cancer
ChiCTR2500105081Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tunlametinib, vemurafenib and cetuximab in colorectal cancer (CRC), sponsored by Ruijin Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tunlametinibvemurafenibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500105081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105081.